S_ry The acquisition of the mulidrug resistance phenotype in human tumours is associated with an overexpression of the 170 kDa P-glycoprotein encoded by the multidrug resistance I (MDR1) gene, and also with a 190 kDa membrane ATP-binding protein encoded by a multidrug resistance-associated protein (MRP) gene. Human bladder cancer is a highly malignant neoplasm which is refractory to anti-cancer chemotherapy. In order to understand the hanism underying multidrug resistance in bladder cancer, we established three doxorubicin-resistant cel lines, T24/ADM-1, T24/ADM-2 and KK47/ADM, and one vincristine-resistant cell line, T24/VCR, from human bladder cancer T24 and KK47 cells respectively. Both T24/ADM-1 and T24/ADM-2 cells which had elevated MRP mRNA levels showed both a cross-resistance to etoposide and a decreased intracellular accumulation of etoposide. T24/VCR cells which had elevated levels of MDR1 mRNA and P-glycoprotein but not of MRP mRNA, showed cross-resistce to doxorubicin. On the other hand, KK47/ADM cells, which had elevated levels of both MRP and MDR1 mRNA and a decreased level of topoisomerase II mRNA, were found to be cross-resistant to etoposide, vincristine and a camptothecin derivative, CT-1I 1. Our present study demonstrates a concomitant induction of increased levels of MRP mRNA, decreased levels of topoisomerase II mRNA and decreased drug accumulation during development of multidrug resistance in human bladder cancer cells. The enhanced expression of the MRP gene is herein discussed in a possible correlation with the decreased expression of the topoisomerase II gene.
The overexpression of membrane P-glycoprotein (P-gp) with Mr of 170 kDa, encoded by the human multidrug resistance 1 (MDRl) gene, is often associated with the acquisition of the multidrug resistance phenotype (Bradley et al., 1988; Gottesman and Pastan, 1988) . The reduced drug retention in P-gp-overexpressing cells is due to an enhanced active efflux of anti-cancer agents. The MDR1 gene is often expressed in various tumours from cancer patients (Goldstein et al., 1989) , but the expression of the MDRI-encoded P-gp is not always coupled with the acquisition of multidrug-resistant phenotypes in human tumours. One other form of multidrug resistance, in which altered topoisomerase II activity is involved (Takano et al., 1992) , has been referred to as atypical multidrug resistance (Beck et al., 1987) . Another form of multidrug resistance is non-Pgp-mediated multidrug resistance. This type of multidrug resistance has been reported in doxorubicin-selected lung carcinoma cell lines (Mirski et al., 1987; Scheper et al., 1993; Barrand et al., 1994 ) and a leukaemia cell line (Marsh et al., 1987) among others. Expression of a 190 kDa vesicular glycoprotein (Krishnachary et al., 1993) and a 110 kDa membrane glycoprotein (Scheper et al., 1993) appears to be associated with the non-P-gp-mediated multidrug resistance in some of these cell lines. Cole et al. (1992) have isolated a gene named multidrug resistance-associated protein (MRP) from a doxorubicin-sekcted small-cell lung carcinoma cell line (H69AR): H69AR cells have a MDR phenotype, but do not overexpress P-gp (Mirski et al., 1987) . This MRP gene is amplified in H69AR cells as well as in several other cell lines that overexpress this mRNA (Slovak et al., 1993; Zaman et al., 1993) . MDR1 and MRP are both members of the ATP-binding cassette (ABC) superfamily transport system described by Hyde et al. (1990) , but have very little sequence homology with each other outside the nucleotide-binding domains (Cole et al., 1992) .
Anti-cancer agents such as etoposide, cisplatin, vincristine, vinblastine, doxorubicin and others have been employed in the therapy of human bladder cancer, but their therapeutic effects are not satisfactory (Harry et al., 1987; Stemnberg et al., 1988) . Resistance to anti-cancer agents in bladder cancer cells in culture and bladder tumour in vivo is sometimes associated with an enhanced expression of P-gp or MDR1 gene (Naito et al., 1992; Shinohara et al., 1993; Kimiya et al., 1992 (Taya et al., 1977) and T24 (Bubenik et al., 1973) were established from transitional cell carcinoma of the bladder and were used as parental cell lines from which multidrug-resistant cells were developed. A doxorubicinresistant cell line (KK47/ADM) from KK47 cells was established as described previously (Kimiya et al., 1992 (Table I ). As shown in Table I , KK47/ADM cells were an 18.7-fold resistant to doxorubicin and 3.5-to 4.6-fold resistant to etoposide, vincristine and CPT-l1 compared with KK47 cells. In contrast, T24/ADM-1 and T24/ ADM-2 showed 4.8-to 10.5-fold higher resistance to doxorubicin and etoposide than T24, but only showed 1.2-to 1.9-fold higher resistance to vincrisine. T24/VCR cells showed 6.8-fold and 15.1-fold higher resistance to doxorubicin and vincristine, respectively, but only 1.8-to 3.1-fold higher resistance to etoposide and CPT-l 1. The KK47/ADM, T24/ADM-1 and T24/ADM-2 cell lines were not cross-resistant to cisplatin, while T24/VCR showed 2-fold higher resistance to cisplatin than T24 (Table I) . Thus the four cell lines, KK47/ADM, T24/ADM-1, T24/ADM-2 and T24/VCR, all had acquired a multidrug resistance phenotype, but each cell line appeared to show a unique cross-resistance pattern.
Cellular accumulation of vincristine, etoposide and doxorubicin The cellular accumulation of vincristine, etoposide and doxorubicin is often reduced in multidrug-resistant cell lines (Kohno et al., 1988; Matsuo et al., 1990 Doxorubicin accumulation in T24, T24/ADM-2 and T24/ VCR cells was compared using fluorescence microscopy. As seen in Figure 3a , doxorubicin accumulated in the nuclei of T24 cells when incubated for 40 min with the drug. This was followed by a gradual decrease in intranuclear doxorubicin concentration during further incubation for 120 min in the absence of the drug. T24, T24/ADM-2 and T24/VCR cells were first incubated with doxorubicin at 1 jLg ml-', 2 jig ml-' and 4 Lg ml-', respectively, for 40 min. The level of doxorubicin accumulation in the nuclei of T24/ADM-2 and T24/ VCR cells was similar to that of T24 cells when incubated with drug for 40 min at 37C (Figure 3) . However, doxorubicin in nuclei was almost completely removed from T24/ ADM-2 and T24/VCR cells after further incubation for 120 min in the absence of drug (Figure 3d and f) , while doxorubicin still remained in nuclei of the parental T24 cells (Figure 3b ). Figure  4b , Table II ). The cellular MDR1 mRNA level in KK47/ ADM cels was similar to that of a multidrug-resistant ceUl line, VJ-300, which overexpresses P-gp, derived from human epidermoid cancer KB ceUls (Kohno et al., 1988) (Cole et al., 1992; Grant et al., 1994) , the MRP-specific probe hybridised to 6.5 kb RNA species (Figure 4b Figure 4a and b.
The enhanced expression of MRP mRNA in doxorubicinresistant small-ell lung cancer cell lines which were selected in vitro is due to an amplification of the MRP gene (Cole et al., 1992; Zaman et al., 1993) . To determine whether the elevated levels of MRP mRNA in KK47/ADM, T24/ADM-l and T24/ADM-2 cells were due to an amplification of this gene, Southern blot analysis of EcoRI-digested genomic DNA from these cells was performed. As shown in Figure 5 and Table II , an approximately 17-fold amplification of the MDR1 gene was observed in KK47/ADM cells compared with KK47 cells, but no amplification of the MDR1 gene was apparent in the T24/ADM-1, T24/ADM-2 and T24/VCR cells. We could observe 2-and 4-fold amplification of the MRP gene in T24/ADM-1 and T24/ADM-2, respectively, whereas no amplification was observed in KK47/ADM cells ( Figure 5 ). In T24/VCR cells, the MDR1 mRNA level was appreciably increased, but no apparent amplification of the MDR1 gene was observed ( Figure 5 , Table II ). KK47/ADM cells appeared to overexpress both MRP and MDR1 mRNA. Western blot analysis was performed to confirm whether both the 190 kDa MRP gene product and the 170 k.Da P-gp in KK47/ADM cells also increased ( Figure  6 ). Although the parental KK47 cells expressed multidrug resistance-associated protein, KK47/ADM had about 3-fold more MRP gene product than KK47 cells. Furthermore, P-gp was also overexpressed in KK47/ADM cells, but since it was not detectable in parental KK47 cells the relative increase in P-gp expression could not be calculated ( Figure 6 ). P-gp-mediated drug-resistant cells exhibit elevated levels of drug resistance to vinca alkaloids (vincristine) and anthracylcines (daunomycin, doxorubicin), colchicine and actinomycin D, as well as resistance to topoisomerase II-targeting agents such as etoposide and teniposide (Bradley et al., 1988; Kohno et al., 1989 (Grant et al., 1994) .
The enhanced expression of MRP mRNA in most resistant cell lines which are selected in vitro is often due to amplification of the MRP gene (Cole et al., 1992; Slovak et al.. 1993; Zaman et al., 1993) . On the other hand, Abe et al. (1994) recently reported that expression of the MRP gene is enhanced in some human glioma cells which show spontaneous multidrug resistance to vincristine, doxorubicin and etoposide, and also that the higher MRP mRNA levels are due not to gene amplification, but to transcriptional or posttranscriptional events. Consistent with these glioma cell lines, the increased MRP mRNA levels in KK47/ADM bladder cells appear also to be due to transcriptional or posttranscriptional activation, rather than to gene amplification. By contrast, amplification of the MRP gene is probably the main mechanism underlying increased MRP mRNA levels in both T24/ADM-1 and T24/ADM-2 cells.
The accumulation of vincristine is often decreased in cancer cell lines overexpressing P-gp or the MDRl gene, and is consistent with the findings of our previous study (Nakagawa et al., 1986; Shiraishi et al., 1987; Kohno et al., 1988) . A decreased accumulation of etoposide was observed in bladder cancer cell lines overexpressing the MRP gene or its product. Doxorubicin in the nuclei of T24/ADM-2 cells was almost completely removed after incubation for 120 min in the absence of drug, but this was not the case in the parental T24 cells. For the most part, decreased accumulation of etoposide or doxorubicin is observed in non-P-gpmediated drug-resistant cell lines which overexpress MRP (Zaman et al., 1973; Krishnamachary et al., 1993; Scheneider et al., 1994) . Consistent with previous reports (Cole et al., 1991; Scheneider et al., 1994) , MRP might be somehow involved in translocation of the anti-cancer drug from nuclei into the cytoplasm rather than outward transport from cytoplasms. Marquardt and Center (1992) have demonstrated that doxorubicin is localised at perinuclear regions when the drug is removed from culture medium for non-P-gp-mediated multidrug-resistant leukaemia cells overexpressing MRP. Further study is required to determine how MRP modulates the intracellular localisation of doxorubicin or etoposide.
In our present study, the enhanced expression of the MRP gene, the reduced expression of the topoisomerase II and the decreased drug accumulation were all concomitantly observed in non-P-gp-mediated drug-resistant human bladder cells. 
